Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

• Status: Unknown status
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1 study to test the safety of escalating doses of elesclomol sodium given to patients with advanced myeloid leukemia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Synta Pharmaceuticals Corp.

Criteria

Inclusion Criteria:

• Adults with cytologically confirmed Acute Myeloid Leukemia (AML) that has relapsed after the completion of induction and/or consolidation therapy or has failed to respond to standard induction therapy

• ECOG performance status of 0-2

• Acceptable organ and marrow function during the screening period as defined by the protocol

• Reliable venous access suitable for study drug infusions

Exclusion Criteria:

• Significant cardiovascular disease

• Candidates for hematopoietic stem cell transplant

• Women who are pregnant or breast-feeding

• Prior treatment with chronic immunosuppressants

• Other clinically significant uncontrolled conditions